Investigational drug · Phase 3
Combined metabolic activators
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alzheimer Disease, Gout Disease.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Combined metabolic activators"
First trial start
2025
Sep 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Combined metabolic activators", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease
- Gout Disease
Approved drugs for the same conditions: Alzheimer's disease · Gout · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Combined metabolic activators" as an intervention, largest first.
- Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's DiseasePivotal-lookingRecruiting
ScandiBio Therapeutics ABIndustry
NCT07062198 · 845 participants (planned) · Start Sep 12, 2025 · Primary completion Sep 2026
Drug: Combined metabolic activators · For: Alzheimer Disease
Sites: Alanya, Turkey (Türkiye); Erzurum, Turkey (Türkiye); Istanbul, Turkey (Türkiye) · 8 sites in all
- Combined Metabolic Activator Supplementation in Subjects Diagnosed With GoutPivotal-lookingRecruiting
ScandiBio Therapeutics ABIndustry
NCT07889284 · 336 participants (planned) · Start Nov 4, 2026 · Primary completion Feb 2027
Drug: Combined metabolic activators · For: Gout Disease
Sites: Ankara, Turkey (Türkiye); Antalya, Turkey (Türkiye); Erzurum, Turkey (Türkiye) · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeting mitochondrial metabolism with combined metabolic activators.
Yang H, Kong X, Liao X, et al. · Trends Endocrinol Metab 2026
- Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial.
Yulug B, Altay O, Li X, et al. · Brain Commun 2025
- Retraction notice to "Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases" [Life Sci. 314 (2023) 121325].
Turkez H, Altay O, Yildirim S, et al. · Life Sci 2024
- Combined Metabolic Activators with Different NAD+ Precursors Improve Metabolic Functions in the Animal Models of Neurodegenerative Diseases.
Altay O, Yang H, Yildirim S, et al. · Biomedicines 2024
- The acute effect of different NAD+ precursors included in the combined metabolic activators.
Li X, Yang H, Jin H, et al. · Free Radic Biol Med 2023
- Longitudinal metabolomics analysis reveals the acute effect of cysteine and NAC included in the combined metabolic activators.
Yang H, Li X, Jin H, et al. · Free Radic Biol Med 2023
Also in development for Alzheimer Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- DMB-IINN: Latrepirdine, DimebonPhase 32 trials
Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type
- AR1001Phase 31 trial
AriBio Co., Ltd. · Alzheimer Disease
- XTR006[18F]MK 6240, FlorquinitauPhase 31 trial
Sinotau Pharmaceutical Group · Alzheimer Disease, Neurofibrillary Tangle
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.